Glaukos Corporation

Glaukos Corporation is a medical technology company specializing in the development and commercialization of novel ophthalmic therapeutic treatments. Its key focus is on glaucoma, one of the leading causes of irreversible blindness worldwide, and it develops minimally invasive treatment solutions for this chronic eye disease. The company's flagship products include iStent, iStent Inject, and iStent Supra, which are designed to lower intraocular pressure, a major risk factor for glaucoma. Glaukos Corporation also explores other ocular disorders and continues to innovate in the fields of corneal disorders and retinal diseases. By targeting unmet medical needs with pioneering devices and drugs, the company plays a crucial role in advancing eye care and improving the quality of life for patients globally. Established in 1998 and headquartered in San Clemente, California, Glaukos has become a significant player in the ophthalmology sector, influencing practices not just in the U.S. but internationally.